ZAI LAB LIMITED Government Assistance Nonoperating Income
ZAI LAB LIMITED (ZLAB) reported Government Assistance Nonoperating Income of $106.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Income Statement › Other Income
us-gaap:GovernmentAssistanceNonoperatingIncome · last filed 2026-05-07
- ZAI LAB LIMITED government assistance nonoperating income for the quarter ending 2026-03-31 was $106.00K, a 562.50% increase year-over-year.
- ZAI LAB LIMITED government assistance nonoperating income for the quarter ending 2025-12-31 was $1.14M, a 16.06% increase year-over-year.
- ZAI LAB LIMITED government assistance nonoperating income for the quarter ending 2025-09-30 was $854.00K, a 77.88% decline year-over-year.
- ZAI LAB LIMITED government assistance nonoperating income for the quarter ending 2025-06-30 was $3.85M, a 620.97% increase year-over-year.
- ZAI LAB LIMITED government assistance nonoperating income for fiscal 2025 was $5.86M, a 28.25% decline from fiscal 2024.
- ZAI LAB LIMITED government assistance nonoperating income for fiscal 2024 was $8.17M, a 235.80% increase from fiscal 2023.
- ZAI LAB LIMITED government assistance nonoperating income for fiscal 2023 was $2.43M, a 78.79% decline from fiscal 2022.
- ZAI LAB LIMITED government assistance nonoperating income for fiscal 2022 was $11.47M.
| Period end | Government Assistance Nonoperating Income 3 month | Government Assistance Nonoperating Income 6 month | Government Assistance Nonoperating Income 9 month | Government Assistance Nonoperating Income 12 month |
|---|---|---|---|---|
| 2026-03-31 | $106.00K 10-Q · filed 2026-05-07 | $1.25M derived: sum of 2 quarters · filed 2026-05-07 | $2.10M derived: sum of 3 quarters · filed 2026-05-07 | $5.95M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.00M derived: sum of 2 quarters · filed 2026-02-26 | $5.85M derived: sum of 3 quarters · filed 2026-02-26 | $5.86M 10-K · filed 2026-02-26 |
| 2025-09-30 | $854.00K 10-Q · filed 2025-11-06 | $4.70M derived: sum of 2 quarters · filed 2025-11-06 | $4.72M 10-Q · filed 2025-11-06 | $5.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-06-30 | $3.85M 10-Q · filed 2025-08-07 | $3.87M 10-Q · filed 2025-08-07 | $4.85M derived: sum of 3 quarters · filed 2026-05-07 | $8.71M derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-03-31 | $16.00K 10-Q · filed 2026-05-07 | $1.00M derived: sum of 2 quarters · filed 2026-05-07 | $4.86M derived: sum of 3 quarters · filed 2026-05-07 | $5.39M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $984.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.84M derived: sum of 2 quarters · filed 2026-02-26 | $5.38M derived: sum of 3 quarters · filed 2026-02-26 | $8.17M 10-K · filed 2026-02-26 |
| 2024-09-30 | $3.86M 10-Q · filed 2025-11-06 | $4.39M derived: sum of 2 quarters · filed 2025-11-06 | $7.19M 10-Q · filed 2025-11-06 | $8.87M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $534.00K 10-Q · filed 2025-08-07 | $3.33M 10-Q · filed 2025-08-07 | $5.00M derived: sum of 3 quarters · filed 2026-02-26 | $5.67M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.79M 10-Q · filed 2025-05-08 | $4.47M derived: sum of 2 quarters · filed 2026-02-26 | $5.14M derived: sum of 3 quarters · filed 2026-02-26 | $5.22M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.35M derived: sum of 2 quarters · filed 2026-02-26 | $2.43M derived: sum of 3 quarters · filed 2026-02-26 | $2.43M 10-K · filed 2026-02-26 |
| 2023-09-30 | $671.00K 10-Q · filed 2024-11-12 | $754.00K derived: sum of 2 quarters · filed 2024-11-12 | $754.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $83.00K 10-Q · filed 2024-08-06 | $83.00K 10-Q · filed 2024-08-06 | ||
| 2022-12-31 | $11.47M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |